← All Acumen Pharmaceuticals, INC filings

Acumen Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ABOS
Acumen Pharmaceuticals, INC
10-K: Acumen Pharmaceuticals Reports 2025 Losses, Advances AD Pipeline
Acumen Pharmaceuticals reported increased net losses for 2025 while advancing its lead Alzheimer's drug candidate, sabirnetug, and expanding its next-generation brain delivery platform.
NASDAQ
ABOS
Acumen Pharmaceuticals, INC
10-K: Acumen Pharmaceuticals Reports 2024 Financial Results, Provides Business Update
Acumen Pharmaceuticals details its financial performance for 2024 and provides an update on its clinical development programs, including the Phase 2 ALTITUDE-AD trial for sabirnetug.
NASDAQ
ABOS
Acumen Pharmaceuticals, INC
10-K: Acumen Pharmaceuticals Leases Newton Office Space and Outlines Financials in 10-K Filing
Acumen Pharmaceuticals secures office space in Newton, MA, while also detailing financial performance and future plans in its annual 10-K filing.